Intervacc AB

Equities

IVACC

SE0009607252

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:32 2024-04-26 am EDT			5-day change	1st Jan Change
4.175 ^SEK	+3.34%		+0.85%	-34.04%

Mar. 04	Intervacc AB Announces Changes in the Nomination Committee	CI
Feb. 28	Intervacc's Acting CEO Assumes Role Permanently	MT

Veterinary Medicines Directorate Extends the Shelf Life for Intervacc AB's Strangvac, a Vaccine Against Equine Strangvac, to 33 Months

May 08, 2023 at 09:00 am EDT

Intervacc AB (publ) announced that the Veterinary Medicines Directorate (VMD) has, after reviewing stability data, approved the extension of the shelf life for Strangvac, to 33 months from previously 24 months.

Latest news about Intervacc AB

Intervacc AB Announces Changes in the Nomination Committee	Mar. 04	CI
Intervacc's Acting CEO Assumes Role Permanently	Feb. 28	MT
Jonas Sohlman Appoints as New CEO for Intervacc AB	Feb. 28	CI
Intervacc AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 16	CI
Intervacc AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 16	CI
Intervacc, Moredun Scientific Receive Eurostars Grant for Vaccine Against Pig Infection	Feb. 08	MT
Intervacc AB Awards Prestigious Eurostars Grant to Advance Their New Prototype Vaccine Against Streptococcus Suis Infection in Pigs	Feb. 07	CI
Intervacc AB Announces Changes in the Nomination Committee	Dec. 21	CI
Intervacc AB Announces Executive Changes	Nov. 23	CI
Intervacc Secures US Patent for Vaccine Against Infectious Disease Targeting Pigs	Nov. 23	MT
Intervacc AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
Intervacc AB Announces Composition of Nomination Committee	23-10-30	CI
Intervacc AB(OM:IVACC) dropped from S&P Global BMI Index	23-09-18	CI
Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI
Intervacc President, CEO Resigns; Interim Successor Named	23-08-21	MT
Intervacc AB Announces Executive Changes	23-08-21	CI
Intervacc AB Announces Executive Changes	23-08-21	CI
Intervacc AB Receives Grant to Optimise Production Processes for A Fusion Protein from Vinnova	23-08-17	CI
Swedish Animals Vaccine Maker Intervacc Partners With Testa Center	23-07-11	MT
Intervacc to Collaborate with Testa Center to Optimise Production Processes for Their Prototype Vaccine for Pigs	23-07-11	CI
Intervacc AB Approves the Election of Boel Sundvall as Board Member	23-06-07	CI
The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 Months	23-05-17	CI
Veterinary Medicines Directorate Extends the Shelf Life for Intervacc AB's Strangvac, a Vaccine Against Equine Strangvac, to 33 Months	23-05-08	CI
Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-03	CI
Intervacc Slumps 14% Amid Plan to Initiate SEK100 Million Rights Offering	23-04-19	MT

Chart Intervacc AB

Duration

Period

More charts

Company Profile

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Companyâs candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Sector

Biotechnology & Medical Research

Calendar

2024-05-16 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Intervacc AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INTERVACC AB	-34.04%	28.84M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs